Edition:
United States

Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

32.06USD
9:48am EST
Change (% chg)

$0.17 (+0.52%)
Prev Close
$31.89
Open
$31.78
Day's High
$32.06
Day's Low
$31.78
Volume
5,805
Avg. Vol
129,780
52-wk High
$42.00
52-wk Low
$25.76

Latest Key Developments (Source: Significant Developments)

Hutchison China Meditech says ‍underwriters elected to purchase an additional 1.5 mln ADSs
Friday, 27 Oct 2017 07:10am EDT 

Oct 27 (Reuters) - Hutchison China Meditech Ltd :UNDERWRITERS HAVE ELECTED TO PURCHASE AN ADDITIONAL 1.5 MILLION ADSS AT OFFERING PRICE OF US$26.50 PER ADS.‍TOTAL GROSS PROCEEDS OF OFFERING IS APPROXIMATELY US$301.3 MILLION​.  Full Article

Chi-Med reports preliminary phase II data on fruquintinib combination
Monday, 16 Oct 2017 02:00am EDT 

Oct 16 (Reuters) - Hutchison China Meditech Ltd :CHI-MED REPORTS PRELIMINARY PHASE II DATA ON FRUQUINTINIB COMBINATION IN FIRST-LINE LUNG CANCER.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY RESULTS IN 17 EFFICACY EVALUABLE PATIENTS SHOWED AN ORR OF 76 PERCENT AND A DCR OF 100 PERCENT​.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY DATA FROM PHASE II TRIAL DEMONSTRATED PROMISING EFFICACY AND AN ACCEPTABLE SAFETY PROFILE​.  Full Article

Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares
Monday, 3 Apr 2017 07:59am EDT 

Hutchison China Meditech Ltd :Hutchison China Meditech Ltd - files to say may offer to sell in one or more offerings American Depositary Shares representing ordinary shares - SEC filing.  Full Article

Hutchison China Meditech FY group revenue up 21 pct
Monday, 13 Mar 2017 03:00am EDT 

Hutchison China Meditech Ltd : FY group revenue up 21 pct to $216.1 million .FY net income attributable to Chi-Med of $11.7 million versus $8.0 million year ago.  Full Article

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

No consensus analysis data available.